{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:44:26Z","timestamp":1785368666927,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the short- and long-term complication profiles of Rezum and Urolift using standardized approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed published data from the pivotal randomized trials of Rezum and Urolift. The severity of complications was independently graded by urologists using the Accordion Severity Grading System, developed by the American College of Surgeons National Surgical Quality Improvement Program. Short- (3\u00a0months) and long-term (5\u00a0years) complication rates were assessed. Long-term complications included medical retreatment, surgical retreatment, and surgical implant removal. We calculated the weighted postoperative morbidity index (PMI) values (0\u20131 scale) for each procedure and performed Monte Carlo simulations to account for uncertainty in complication rates and severities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Short-term PMI values were similar between the Rezum (0.091) and Urolift (0.092) groups, with dysuria, hematuria, pain, and urinary urgency most commonly reported. Over 5\u00a0years, the cumulative complication rates were 15.4% for Rezum and 33.6% for Urolift. The associated 5-year PMI was 0.055 for Rezum and 0.165 for Urolift, indicating a three-fold higher long-term severity-weighted complication burden with Urolift. Monte Carlo simulations confirmed the robustness of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified significant differences in the long-term complication profiles of Rezum and Urolift when considering both the incidence and severity of postoperative complications. These findings may help guide clinical decision-making when selecting minimally invasive surgical options for BPH\/LUTS treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-025-04704-x","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T16:26:43Z","timestamp":1753806403000},"page":"545-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing complications of Rezum and Urolift for BPH\/LUTS using the Accordion Severity Grading System"],"prefix":"10.1007","volume":"58","author":[{"given":"Kevin","family":"McVary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandip","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-1885","authenticated-orcid":false,"given":"Larry E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"Suppl 3","key":"4704_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1464-410X.2009.08371.x","volume":"103","author":"KS Coyne","year":"2009","unstructured":"Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS et al (2009) The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 103(Suppl 3):4\u201311","journal-title":"BJU Int"},{"issue":"3","key":"4704_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","volume":"68","author":"L Cindolo","year":"2015","unstructured":"Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R et al (2015) Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68(3):418\u2013425","journal-title":"Eur Urol"},{"issue":"2","key":"4704_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ijcp.12241","volume":"68","author":"JS Koh","year":"2014","unstructured":"Koh JS, Cho KJ, Kim HS, Kim JC (2014) Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Clin Pract 68(2):197\u2013202","journal-title":"Int J Clin Pract"},{"issue":"4","key":"4704_CR4","first-page":"1","volume":"69","author":"T Zabkowski","year":"2018","unstructured":"Zabkowski T, Saracyn M (2018) Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol 69(4):1\u20136","journal-title":"J Physiol Pharmacol"},{"issue":"3","key":"4704_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/JU.0000000000000319","volume":"202","author":"HE Foster","year":"2019","unstructured":"Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ et al (2019) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol 202(3):592\u2013598","journal-title":"J Urol"},{"issue":"3","key":"4704_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.juro.2018.05.048","volume":"200","author":"HE Foster","year":"2018","unstructured":"Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS et al (2018) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 200(3):612\u2013619","journal-title":"J Urol"},{"issue":"2","key":"4704_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prnil.2017.01.007","volume":"5","author":"D Christidis","year":"2017","unstructured":"Christidis D, McGrath S, Perera M, Manning T, Bolton D, Lawrentschuk N (2017) Minimally invasive surgical therapies for benign prostatic hypertrophy: the rise in minimally invasive surgical therapies. Prostate Int 5(2):41\u201346","journal-title":"Prostate Int"},{"issue":"5","key":"4704_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.euf.2024.04.006","volume":"10","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Manfredi C, Licari LC, Bologna E, Franco A, Pandolfo SD et al (2024) Benign prostatic hyperplasia surgery: a snapshot of trends, costs, and surgical retreatment rates in the USA. Eur Urol Focus 10(5):826\u2013832","journal-title":"Eur Urol Focus"},{"issue":"7","key":"4704_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11934-019-0903-7","volume":"20","author":"Z Green","year":"2019","unstructured":"Green Z, Westwood J, Somani BK (2019) What\u2019s new in Rezum: a transurethral water vapour therapy for BPH. Curr Urol Rep 20(7):39","journal-title":"Curr Urol Rep"},{"issue":"1","key":"4704_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5152\/tud.2022.21149","volume":"48","author":"A Denisenko","year":"2022","unstructured":"Denisenko A, Somani B, Agrawal V (2022) Recent advances in UroLift: a comprehensive overview. Turk J Urol 48(1):11\u201316","journal-title":"Turk J Urol"},{"issue":"1","key":"4704_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT et al (2024) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol 211(1):11\u201319","journal-title":"J Urol"},{"issue":"2","key":"4704_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/SLA.0b013e3181afde41","volume":"250","author":"SM Strasberg","year":"2009","unstructured":"Strasberg SM, Linehan DC, Hawkins WG (2009) The accordion severity grading system of surgical complications. Ann Surg 250(2):177\u2013186","journal-title":"Ann Surg"},{"key":"4704_CR13","volume":"203","author":"K McVary","year":"2020","unstructured":"McVary K, Roehrborn C (2020) Five year results of the prospective randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 203:e1021","journal-title":"J Urol"},{"issue":"3","key":"4704_CR14","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24(3):8802\u20138813","journal-title":"Can J Urol"},{"issue":"2","key":"4704_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jss.2013.11.1084","volume":"190","author":"CL Klos","year":"2014","unstructured":"Klos CL, Safar B, Hunt SR, Wise PE, Birnbaum EH, Mutch MG et al (2014) Accordion complication grading predicts short-term outcome after right colectomy. J Surg Res 190(2):510\u2013516","journal-title":"J Surg Res"},{"issue":"4","key":"4704_CR16","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.jtcvs.2015.11.058","volume":"151","author":"EG Chan","year":"2016","unstructured":"Chan EG, Bianco V 3rd, Richards T, Hayanga JW, Morrell M, Shigemura N et al (2016) The ripple effect of a complication in lung transplantation: evidence for increased long-term survival risk. J Thorac Cardiovasc Surg 151(4):1171\u20131179","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"4704_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jamcollsurg.2012.04.030","volume":"215","author":"PW Carrott","year":"2012","unstructured":"Carrott PW, Markar SR, Kuppusamy MK, Traverso LW, Low DE (2012) Accordion severity grading system: assessment of relationship between costs, length of hospital stay, and survival in patients with complications after esophagectomy for cancer. J Am Coll Surg 215(3):331\u2013336","journal-title":"J Am Coll Surg"},{"issue":"3","key":"4704_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jamcollsurg.2009.12.004","volume":"210","author":"MR Porembka","year":"2010","unstructured":"Porembka MR, Hall BL, Hirbe M, Strasberg SM (2010) Quantitative weighting of postoperative complications based on the accordion severity grading system: demonstration of potential impact using the american college of surgeons national surgical quality improvement program. J Am Coll Surg 210(3):286\u2013298","journal-title":"J Am Coll Surg"},{"issue":"8","key":"4704_CR19","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.ijar.2014.04.018","volume":"55","author":"F Aguirre","year":"2014","unstructured":"Aguirre F, Destercke S, Dubois D, Sallak M, Jacob C (2014) Inclusion\u2013exclusion principle for belief functions. Int J Approx Reason 55(8):1708\u20131727","journal-title":"Int J Approx Reason"},{"issue":"2","key":"4704_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/JU.0000000000001073","volume":"204","author":"KT McVary","year":"2020","unstructured":"McVary KT, Kaplan SA (2020) A Tower of babel in today\u2019s urology: disagreement in concepts and definitions of lower urinary tract symptoms\/benign prostatic hyperplasia re-treatment. J Urol 204(2):213\u2013214","journal-title":"J Urol"},{"key":"4704_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-14-1","volume":"14","author":"J Beilan","year":"2014","unstructured":"Beilan J, Strakosha R, Palacios DA, Rosser CJ (2014) The Postoperative Morbidity Index: a quantitative weighing of postoperative complications applied to urological procedures. BMC Urol 14:1","journal-title":"BMC Urol"},{"issue":"2","key":"4704_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155\u2013163","journal-title":"J Chiropr Med"},{"key":"4704_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/JU0000000000001132","author":"LE Miller","year":"2020","unstructured":"Miller LE, Chughtai B, Dornbier RA, McVary KT (2020) Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol. https:\/\/doi.org\/10.1097\/JU0000000000001132","journal-title":"J Urol"},{"issue":"4","key":"4704_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17434440.2020.1742699","volume":"17","author":"LE Miller","year":"2020","unstructured":"Miller LE, Te AE, Bhattacharyya SK, Lilienfeld S, Dornbier RA, McVary KT (2020) A novel metric for treatment durability in clinical trials of minimally invasive treatments for benign prostatic hyperplasia. Expert Rev Med Devices 17(4):365\u2013369","journal-title":"Expert Rev Med Devices"},{"issue":"10","key":"4704_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.5489\/cuaj.8334","volume":"17","author":"NS Dean","year":"2023","unstructured":"Dean NS, Assmus MA, Lee MS, Guo JN, Krambeck AE (2023) Benign prostatic hyperplasia surgical re-treatment after prostatic urethral lift a narrative review. Can Urol Assoc J 17(10):353\u2013359","journal-title":"Can Urol Assoc J"},{"issue":"Suppl 1","key":"4704_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/anae.14513","volume":"74","author":"MPW Grocott","year":"2019","unstructured":"Grocott MPW, Edwards M, Mythen MG, Aronson S (2019) Peri-operative care pathways: re-engineering care to achieve the \u201ctriple aim.\u201d Anaesthesia 74(Suppl 1):90\u201399","journal-title":"Anaesthesia"},{"issue":"3","key":"4704_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.urpr.2016.12.002","volume":"4","author":"F Gaylis","year":"2017","unstructured":"Gaylis F, Gaylis G (2017) White paper on MACRA: past, present and future. Urol Pract 4(3):200\u2013209","journal-title":"Urol Pract"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04704-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04704-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04704-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:21:52Z","timestamp":1770042112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04704-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4704"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04704-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kevin McVary discloses consultancy and PI for Astellas, Boston Scientific, NIDDK, Merck, UroNext, Olympus, and SRS Medical Systems. Bronwyn Long reports no conflicts of interest. Amandip Cheema reports no conflicts of interest. Larry Miller discloses consultancy with Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board approval was obtained for the included studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants before inclusion in the studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}